Anocca AB

Anocca AB is a clinical-stage biotechnology company headquartered in Södertälje, Sweden, specializing in the development of next-generation TCR-T (T-cell receptor-engineered T-cell) immunotherapies. Founded in 2014, the company utilizes a proprietary, industrialized analytical cell biology platform to decode T-cell immunity and engineer highly precise, scalable therapies for solid tumors, as well as potential applications in infectious and autoimmune diseases. The company operates a fully integrated R&D infrastructure, which includes a custom software ecosystem (AnoccaOS) and in-house cGMP-certified manufacturing facilities. Anocca's approach focuses on targeting hard-to-treat cancers by matching patient-specific HLA and tumor mutations with its library of TCR-T constructs, aiming to provide personalized treatment options for broad patient populations.